Emerging drugs for Guillain-Barré syndrome

Expert Opinion on Emerging Drugs

Volumn 16, Issue 1, 2011, Pages 105-120

  Walgaard, Christa ^a   Jacobs, Bart C ^a   Van Doorn, Pieter A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

complement inhibitors; Guillain Barr syndrome; intravenous immunoglobulins; prognosis

Indexed keywords

CORTICOSTEROID; GANGLIOSIDE GM1 ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT;

ARTIFICIAL VENTILATION; CHILL; DIARRHEA; DISABILITY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG ACTIVITY; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MYALGIA; PLASMAPHERESIS; PREDICTOR VARIABLE; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

ANIMALS; COMPLEMENT INACTIVATING AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG DISCOVERY; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; PLASMA EXCHANGE; PROGNOSIS; RESPIRATION, ARTIFICIAL; RESPIRATORY INSUFFICIENCY;

EID: 79952175183     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2011.531699     Document Type: Review

References (112)

1. Hughes RA, Cornblath DR. Guillain-Barre syndrome. Lancet 2005;366(9497):1653-66.
2. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barre syndrome. Lancet Neurol 2008;16(10):939-50.
3. Van Koningsveld R, Van Doorn PA, Schmitz PI, et al. Mild forms of Guillain-Barre syndrome in an epidemiologic survey in The Netherlands. Neurology 2000;54(3):620-5 (Pubitemid 30082928) (Pubitemid 30082928)
4. Ruts L, Drenthen J, Jongen JLM, et al. Pain in Guillain-Barre syndrome. A long-term follow-up study. Neurology 2010;75(16):1439-47
5. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev (Online) 2010;6:CD002063
6. Raphael JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barre syndrome. Cochrane Database Syst Rev (Online) 2002;(2):CD001798
7. Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine (Baltimore) 1969;48(3):173-215
8. McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 1993;33(4):333-42 (Pubitemid 23103964) (Pubitemid 23103964)
9. Uncini A, Manzoli C, Capasso M. Acute motor conduction block neuropathy or acute multifocal motor neuropathy: an attempt at a nosological systematization. Muscle Nerve 2010;41(2):283-5, author reply 85
10. Griffin JW, Li CY, Ho TW, et al. Pathology of the motor-sensory axonal Guillain-Barre syndrome. Ann Neurol 1996;39(1):17-28
11. Nagashima T, Koga M, Odaka M, et al. Continuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barre syndrome. Arch Neurol 2007;64(10):1519-23 (Pubitemid 47572676) (Pubitemid 47572676)
12. Yuki N. Fisher syndrome and Bickerstaff brainstem encephalitis (Fisher-Bickerstaff syndrome). J Neuroimmunol 2009;215(1-2):1-9.
13. Jacobs BC, Rothbarth PH, van der Meche FG, et al. The spectrum of antecedent infections in Guillain-Barre syndrome: a case-control study. Neurology 1998;51(4):1110-15 (Pubitemid 28473409) (Pubitemid 28473409)
14. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol 1979;110(2):105-23 (Pubitemid 10209694) (Pubitemid 10209694)
15. Hughes RA, Charlton J, Latinovic R, Gulliford MC. No association between immunization and Guillain-Barre syndrome in the United Kingdom, 1992 to 2000. Arch Intern Med 2006;166(12):1301-4 (Pubitemid 43967583) (Pubitemid 43967583)
16. Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barre syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998;339(25):1797-802 (Pubitemid 29005783) (Pubitemid 29005783)
17. Van Asseldonk JT, Franssen H, Van den Berg-Vos RM, et al. Multifocal motor neuropathy. Lancet Neurol 2005;4(5):309-19 (Pubitemid 40545042) (Pubitemid 40545042)
18. Kuijf ML, Godschalk PC, Gilbert M, et al. Origin of ganglioside complex antibodies in Guillain-Barre syndrome. J Neuroimmunol 2007;188(1-2):69-73 (Pubitemid 47095018) (Pubitemid 47095018)
19. Kuijf ML, Samsom JN, van Rijs W, et al. TLR4-mediated sensing of Campylobacter jejuni by dendritic cells is determined by sialylation. J Immunol 2010;185(1):748-55 .. This study shows how Campylobacter jejuni leads to activation of dendritic cells and B cells, which may contribute to the production of anti-ganglioside antibodies.
20. Yu RK, Usuki S, Ariga T. Ganglioside molecular mimicry and its pathological roles in Guillain-Barre syndrome and related diseases. Infect Immun 2006;74(12):6517-27 (Pubitemid 44913126) (Pubitemid 44913126)
21. Kaida K, Morita D, Kanzaki M, et al. Ganglioside complexes as new target antigens in Guillain-Barre syndrome. Ann Neurol 2004;56(4):567-71 (Pubitemid 39319349) (Pubitemid 39319349)
22. Hafer-Macko CE, Sheikh KA, Li CY, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996;39(5):625-35 (Pubitemid 26143601) (Pubitemid 26143601)
23. Willison HJ, Halstead SK, Beveridge E, et al. The role of complement and complement regulators in mediating motor nerve terminal injury in murine models of Guillain-Barre syndrome. J Neuroimmunol 2008;201-202:172-82
24. Hughes RA, Wijdicks EF, Benson E, et al. Supportive care for patients with Guillain-Barre syndrome. Arch Neurol 2005;62(8):1194-8 (Pubitemid 41168343) (Pubitemid 41168343)
25. Durand MC, Porcher R, Orlikowski D, et al. Clinical and electrophysiological predictors of respiratory failure in Guillain-Barre syndrome: a prospective study. Lancet Neurol 2006;5(12):1021-8 (Pubitemid 44709969) (Pubitemid 44709969)
26. Walgaard C, Lingsma HF, Ruts L, et al. Prediction of respiratory insufficiency in Guillain-Barre syndrome. Ann Neurol 2010;67(6):781-7
27. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet 1978;2(8093):750-3 (Pubitemid 9034500) (Pubitemid 9034500)
28. The prognosis and main prognostic indicators of Guillain-Barre syndrome. A multicentre prospective study of 297 patients. The Italian Guillain-Barre Study Group. Brain 1996;119(Pt 6):2053-61
29. Sedano MJ, Calleja J, Canga E, Berciano J. Guillain-Barre syndrome in Cantabria, Spain. An epidemiological and clinical study. Acta Neurol Scand 1994;89(4):287-92 (Pubitemid 24159043) (Pubitemid 24159043)
30. Winer JB, Hughes RA, Osmond C. A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value. J Neurol Neurosurg Psychiatry 1988;51(5):605-12
31. Chio A, Cocito D, Leone M, et al. Guillain-Barre syndrome: a prospective, population-based incidence and outcome survey. Neurology 2003;60(7):1146-50 (Pubitemid 36418776) (Pubitemid 36418776)
32. van Koningsveld R, Steyerberg EW, Hughes RA, et al. A clinical prognostic scoring system for Guillain-Barre syndrome. Lancet Neurol 2007;6(7):589-94 (Pubitemid 46921042) (Pubitemid 46921042)
33. Alshekhlee A, Hussain Z, Sultan B, Katirji B. Guillain-Barre syndrome: incidence and mortality rates in US hospitals. Neurology 2008;70(18):1608-13 (Pubitemid 351620316) (Pubitemid 351620316)
34. Dornonville de la Cour C, Jakobsen J. Residual neuropathy in long-term population-based follow-up of Guillain-Barre syndrome. Neurology 2005;64(2):246-53
35. Bernsen RA, de Jager AE, Schmitz PI, van der Meche FG. Long-term impact on work and private life after Guillain-Barre syndrome. J Neurol Sci 2002;201(1-2):13-17 (Pubitemid 34876899) (Pubitemid 34876899)
36. Bernsen RA, de Jager AE, Kuijer W, et al. Psychosocial dysfunction in the first year after Guillain-Barre syndrome. Muscle Nerve 2010;41(4):533-9
37. de Vries JM, Hagemans ML, Bussmann JB, et al. Fatigue in neuromuscular disorders: focus on Guillain-Barre syndrome and Pompe disease. Cell Mol Life Sci 2010;67(5):701-13
38. Merkies IS, Schmitz PI, Samijn JP, et al. Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 1999;53(8):1648-54 (Pubitemid 29530334) (Pubitemid 29530334)
39. Forsberg A, Press R, Einarsson U, et al. Impairment in Guillain-Barre syndrome during the first 2 years after onset: a prospective study. J Neurol Sci 2004;227(1):131-8 (Pubitemid 39491135) (Pubitemid 39491135)
40. Garssen MP, Van Koningsveld R, Van Doorn PA. Residual fatigue is independent of antecedent events and disease severity in Guillain-Barre syndrome. J Neurol 2006;253(9):1143-6 (Pubitemid 44511469) (Pubitemid 44511469)
41. Plasmapheresis and acute Guillain-Barre syndrome. The Guillain-Barre syndrome Study Group. Neurology 1985;35(8):1096-104
42. Efficiency of plasma exchange in Guillain-Barre syndrome. role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barre syndrome. Ann Neurol 1987;22(6):753-61
43. Hughes RA, Swan AV, Raphael JC, et al. Immunotherapy for Guillain-Barre syndrome: a systematic review. Brain 2007;130(Pt 9):2245-57 (Pubitemid 47327619) (Pubitemid 47327619)
44. Schroder A, Linker RA, Gold R. Plasmapheresis for neurological disorders. Expert Rev Neurother 2009;9(9):1331-9
45. Appropriate number of plasma exchanges in Guillain-Barre syndrome. The French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Ann Neurol 1997;41(3):298-306
46. Kleyweg RP, van der Meche FG, Meulstee J. Treatment of Guillain-Barre syndrome with high-dose gammaglobulin. Neurology 1988;38(10):1639-41
47. van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med 1992;326(17):1123-9
48. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Lancet 1997;349(9047):225-30
49. Kleyweg RP, van der Meche FG. Treatment related fluctuations in Guillain-Barre syndrome after high-dose immunoglobulins or plasma-exchange. J Neurol Neurosurg Psychiatry 1991;54(11):957-60
50. Caress JB, Hobson-Webb L, Passmore LV, et al. Case-control study of thromboembolic events associated with IV immunoglobulin. J Neurol 2009;256(3):339-42
51. Caress JB, Kennedy BL, Eickman KD. Safety of intravenous immunoglobulin treatment. Expert Opin Drug Saf 2010;9(6):971-9
52. Stangel M, Kiefer R, Pette M, et al. Side effects of intravenous immunoglobulins in neurological autoimmune disorders - a prospective study. J Neurol 2003;250(7):818-21 (Pubitemid 36898113) (Pubitemid 36898113)
53. Korinthenberg R, Schessl J, Kirschner J. Clinical presentation and course of childhood Guillain-Barre syndrome: a prospective multicentre study. Neuropediatrics 2007;38(1):10-7 (Pubitemid 47226915) (Pubitemid 47226915)
54. Korinthenberg R, Schessl J, Kirschner J, Monting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barre syndrome: a randomized trial. Pediatrics 2005;116(1):8-14
55. Double-blind trial of intravenous methylprednisolone in Guillain-Barre syndrome. Guillain-Barre Syndrome Steroid Trial Group. Lancet 1993;341(8845):586-90
56. Hughes RA, Swan AV, van Koningsveld R, van Doorn PA. Corticosteroids for Guillain-Barre syndrome. Cochrane Database Syst Rev (Online) 2006;(2):CD001446
57. van Koningsveld R, Schmitz PI, Meche FG, et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial. Lancet 2004;363(9404):192-6 (Pubitemid 38114716) (Pubitemid 38114716)
58. Frenzen PD. Economic cost of Guillain-Barre syndrome in the United States. Neurology 2008;71(1):21-7
59. Buzby JC, Allos BM, Roberts T. The economic burden of Campylobacter-associated Guillain-Barre syndrome. J Infect Dis 1997;176(Suppl 2):S192-7 (Pubitemid 27505889) (Pubitemid 27505889)
60. Havelaar AH, de Wit MA, van Koningsveld R, van Kempen E. Health burden in the Netherlands due to infection with thermophilic Campylobacter spp. Epidemiol Infect 2000;125(3):505-22 (Pubitemid 32156840) (Pubitemid 32156840)
61. Bayry J, Kazatchkine MD, Kaveri SV. Shortage of human intravenous immunoglobulin - reasons and possible solutions. Nat Clin Pract 2007;3(3):120-1 (Pubitemid 46403934) (Pubitemid 46403934)
62. Ruts L, Drenthen J, Jacobs BC, et al. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology 2010;74(21):1680-6
63. Gold R, Stangel M, Dalakas MC. Drug insight: the use of intravenous immunoglobulin in neurology - therapeutic considerations and practical issues. Nat Clin Pract 2007;3(1):36-44 (Pubitemid 46056032) (Pubitemid 46056032)
64. Hadden RD, Karch H, Hartung HP, et al. Preceding infections, immune factors, and outcome in Guillain-Barre syndrome. Neurology 2001;56(6):758-65 (Pubitemid 32240096) (Pubitemid 32240096)
65. Kuitwaard K, de Gelder J, Tio-Gillen AP, et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barre syndrome. Ann Neurol 2009;66(5):597-603
66. Kokubun N, Nishibayashi M, Uncini A, et al. Conduction block in acute motor axonal neuropathy. Brain 2010;133(10):2897-908
67. Roozenbeek B, Maas AI, Lingsma HF, et al. Baseline characteristics and statistical power in randomized controlled trials: selection, prognostic targeting, or covariate adjustment? Crit Care Med 2009;37(10):2683-90
68. van Doorn PA, Merkies IS. How to assess new drugs for neuropathies: advances in trial design and methodology. Curr Opin Neurol 2008;21(5):519-26
69. van Nes SI, Faber CG, Merkies IS. Outcome measures in immune-mediated neuropathies: the need to standardize their use and to understand the clinimetric essentials. J Peripher Nerv Syst 2008;13(2):136-47 (Pubitemid 351871606) (Pubitemid 351871606)
70. Merkies IS, Schmitz PI, van der Meche FG, et al. Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 2002;72(5):596-601 (Pubitemid 34462813) (Pubitemid 34462813)
71. Merkies IS, Schmitz PI, Van Der Meche FG, et al. Psychometric evaluation of a new handicap scale in immune-mediated polyneuropathies. Muscle Nerve 2002;25(3):370-7 (Pubitemid 34203213) (Pubitemid 34203213)
72. Graham RC, Hughes RA. A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. J Neurol Neurosurg Psychiatry 2006;77(8):973-6 (Pubitemid 44174089) (Pubitemid 44174089)
73. Garssen MP, Bussmann JB, Schmitz PI, et al. Physical training and fatigue, fitness, and quality of life in Guillain-Barre syndrome and CIDP. Neurology 2004;63(12):2393-5 (Pubitemid 40024359) (Pubitemid 40024359)
74. Garssen MP, Schmitz PI, Merkies IS, et al. Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial. J Neurol Neurosurg Psychiatry 2006;77(1):61-5 (Pubitemid 43022692) (Pubitemid 43022692)
75. Dalakas MC. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 2002;59(12 Suppl 6):S13-21 (Pubitemid 36076544) (Pubitemid 36076544)
76. Farcas P, Avnun L, Frisher S, et al. Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barre syndrome. Lancet 1997;350(9093):1747 (Pubitemid 28036676) (Pubitemid 28036676)
77. Mori I, Parizot C, Dorgham K, et al. Prominent plasmacytosis following intravenous immunoglobulin correlates with clinical improvement in Guillain-Barre syndrome. PLoS ONE 2008;3(5):e2109
78. Scott SC, Goldberg MS, Mayo NE. Statistical assessment of ordinal outcomes in comparative studies. J Clin Epidemiol 1997;50(1):45-55 (Pubitemid 27089206) (Pubitemid 27089206)
79. Wanschitz J, Maier H, Lassmann H, et al. Distinct time pattern of complement activation and cytotoxic T cell response in Guillain-Barre syndrome. Brain 2003;126(Pt 9):2034-42 (Pubitemid 37059443) (Pubitemid 37059443)
80. Halstead SK, Zitman FM, Humphreys PD, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 2008;131(Pt 5):1197-208.
81. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006;355(12):1233-43 (Pubitemid 44427447) (Pubitemid 44427447)
82. Weisman HF, Bartow T, Leppo MK, et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990;249(4965):146-51
83. Jung S, Toyka KV, Hartung HP. Soluble complement receptor type 1 inhibits experimental autoimmune neuritis in Lewis rats. Neurosci Lett 1995;200(3):167-70
84. Halstead SK, Humphreys PD, Goodfellow JA, et al. Complement inhibition abrogates nerve terminal injury in Miller Fisher syndrome. Ann Neurol 2005;58(2):203-10 (Pubitemid 41098878) (Pubitemid 41098878)
85. Nunn MA, Sharma A, Paesen GC, et al. Complement inhibitor of C5 activation from the soft tick Ornithodoros moubata. J Immunol 2005;174(4):2084-91 (Pubitemid 40223951) (Pubitemid 40223951)
86. Fredslund F, Laursen NS, Roversi P, et al. Structure of and influence of a tick complement inhibitor on human complement component 5. Nat Immunol 2008;9(7):753-60 (Pubitemid 351859158) (Pubitemid 351859158)
87. Halstead SK, Humphreys PD, Zitman FM, et al. C5 inhibitor rEV576 protects against neural injury in an in vitro mouse model of Miller Fisher syndrome. J Peripher Nerv Syst 2008;13(3):228-35
88. Phongsisay V, Susuki K, Matsuno K, et al. Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain-Barre syndrome. J Neuroimmunol 2008;205(1-2):101-4
89. Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet 2009;373(9665):759-67
90. Bechtold DA, Yue X, Evans RM, et al. Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecainide. Brain 2005;128(Pt 1):18-28 (Pubitemid 40070516) (Pubitemid 40070516)
91. Garssen MP, van Koningsveld R, van Doorn PA, et al. Treatment of Guillain-Barre syndrome with mycophenolate mofetil: a pilot study. J Neurol Neurosurg Psychiatry 2007;78(9):1012-13 (Pubitemid 47310849) (Pubitemid 47310849)
92. Bensa S, Hadden RD, Hahn A, et al. Randomized controlled trial of brain-derived neurotrophic factor in Guillain-Barre syndrome: a pilot study. Eur J Neurol 2000;7(4):423-6 (Pubitemid 32280904) (Pubitemid 32280904)
93. Zou LP, Ma DH, Wei L, et al. IFN-beta suppresses experimental autoimmune neuritis in Lewis rats by inhibiting the migration of inflammatory cells into peripheral nervous tissue. J Neurosci Res 1999;56(2):123-30 (Pubitemid 29201051) (Pubitemid 29201051)
94. Pritchard J, Gray IA, Idrissova ZR, et al. A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barre syndrome. Neurology 2003;61(9):1282-4 (Pubitemid 37377557) (Pubitemid 37377557)
95. Wollinsky KH, Hulser PJ, Brinkmeier H, et al. CSF filtration is an effective treatment of Guillain-Barre syndrome: a randomized clinical trial. Neurology 2001;57(5):774-80 (Pubitemid 32845493) (Pubitemid 32845493)
96. Klingel R, Heibges A, Fassbender C. Plasma exchange and immunoadsorption for autoimmune neurologic diseases - current guidelines and future perspectives. Atheroscler Suppl 2009;10(5):129-32
97. Willison HJ. The immunobiology of Guillain-Barre syndromes. J Peripher Nerv Syst 2005;10(2):94-112
98. Townson K, Boffey J, Nicholl D, et al. Solid phase immunoadsorption for therapeutic and analytical studies on neuropathy-associated anti- GM1 antibodies. Glycobiology 2007;17(3):294-303 (Pubitemid 46344681) (Pubitemid 46344681)
99. Lin HH, Wang MX, Spies JM, Pollard JD. Effective treatment of experimental autoimmune neuritis with Fc fragment of human immunoglobulin. J Neuroimmunol 2007;186(1-2):133-40 (Pubitemid 46770869) (Pubitemid 46770869)
100. Van Koningsveld R, Schmitz PI, Ang CW, et al. Infections and course of disease in mild forms of Guillain-Barre syndrome. Neurology 2002;58(4):610-14 (Pubitemid 34164944) (Pubitemid 34164944)
101. Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 1956;255(2):57-65
102. Overell JR, Hsieh ST, Odaka M, et al. Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders. Cochrane Database Syst Rev (Online) 2007;(1):CD004761
103. De La Hoz CL, Castro FR, Santos LM, Langone F. Distribution of inducible nitric oxide synthase and tumor necrosis factor-alpha in the peripheral nervous system of Lewis rats during ascending paresis and spontaneous recovery from experimental autoimmune neuritis. Neuroimmunomodulation 2010;17(1):56-66
104. Pan CL, Tseng TJ, Lin YH, et al. Cutaneous innervation in Guillain-Barre syndrome: pathology and clinical correlations. Brain 2003;126(Pt 2):386-97
105. Martinez V, Fletcher D, Martin F, et al. Small fibre impairment predicts neuropathic pain in Guillain-Barre syndrome. Pain 2010;151(1):53-60
106. Garssen MP, van Doorn PA, Visser GH. Nerve conduction studies in relation to residual fatigue in Guillain-Barre syndrome. J Neurol 2006;253(7):851-6 (Pubitemid 44100436) (Pubitemid 44100436)
107. Drenthen J, Maathuis EM, Ruts L, et al. Serial CMAP scan analysis in Guillain-Barre patients. J Peripher Nerv Syst 2008;13(2):167
108. Brown JN, Howard CA, Kemp DW. Modafinil for the treatment of multiple sclerosis-related fatigue. Ann Pharmacother 2010;44(6):1098-103
109. Bai XF, Shi FD, Zhu J, et al. Linomide-induced suppression of experimental autoimmune neuritis is associated with down-regulated macrophage functions. J Neuroimmunol 1997;76(1-2):177-84 (Pubitemid 27272644) (Pubitemid 27272644)
110. Zou LP, Deretzi G, Pelidou SH, et al. Rolipram suppresses experimental autoimmune neuritis and prevents relapses in Lewis rats. Neuropharmacology 2000;39(2):324-33 (Pubitemid 30009827) (Pubitemid 30009827)
111. Ropper AH. Unusual clinical variants and signs in Guillain-Barre syndrome. Arch Neurol 1986;43(11):1150-2 (Pubitemid 17174443) (Pubitemid 17174443)
112. Bickerstaff ER. Brain-stem encephalitis; further observations on a grave syndrome with benign prognosis. Br Med J 1957;1(5032):1384-7